The immune system is a powerful agent against cancer. Small actions initiate large effects…
Yet cancer cells ‘escape’ the immune system and also actively suppress our immune defenses.
- Susavion’s MVPM™ Technology platform is a promising advancement in the field of immunotherapy.
- Carbohydrates are well known to stimulate the immune system and their receptor targets are well defined, but:
- Carbohydrates are poor drug candidates.
- Appropriately designed peptide sequences can mimic the activity of carbohydrates and access the cell surface.
- MVPM Technology enables Susavion to create peptides that bind to and activate key receptors with high specificity and avidity.
- Our proprietary peptides have been shown to successfully activate the immune system and generate anti-tumor responses.
Design innovative peptide based immunotherapies that
bind lectin-type receptors to activate cellular processes.
Why this approach?
Peptide drugs can be designed to selectively activate the immune system to safely respond to the threat of the disease without triggering immunotoxicity.
Benefits of MVPM Technology
- Susavion offers significant expertise in molecular biology and design of immunostimulatory peptides targeting a variety of receptors.
- Enables design of receptor-active peptides with four important attributes:
- High specificity
- High avidity
- Receptor cross-linking
- Immunologic cross-talk
- High development potential in oncology, HIV and other infectious diseases:
- Demonstrated preclinical POC with lead peptides (svL4 and sv6D) in murine models of difficult-to-treat glioblastoma and ovarian cancer.
Susavion’s lead peptides
A series of peptides, sv6D, svL4, svH1C, svH1D and sv6B, are effective at low nanomolar concentrations. sv6D and svL4 effectively block development of ascites that results from progression of ovarian cancer in the peritoneal cavity of mice and extend survival as a monotherapy or in combination with paclitaxel or anti-PD-1 treatment. Peptide svL4 significantly extended life when administered in combination with low doses of radiation in a mouse model in which glioma cells were implanted into brains. Efficacy has also been demonstrated with melanoma, multiple myeloma, breast and renal cancer. svH1C and sv6B block HIV-1 replication of cultures of peripheral blood mononuclear cells in the presence of non-neutralizing antibodies from HIV-positive patients. These synthetic peptide drugs have promise as biological response modifiers and should strongly enhance the innate immune defense in treatment of viral diseases and cancer.